CClinicalTrials.gg
CompletedNCT03821116Updated Nov 4, 2020

Milk and Soured Milk (filmjölk) Intervention on Oxidative Stress and Inflammation

An interventional study of Milk and Soured milk (filmjölk) in Oxidative Stress and Inflammation, sponsored by Uppsala University. Completed at 1 site in Sweden. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-04.

Sponsored by Uppsala University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

This study evaluates a high intake of milk compared with a high intake of soured milk (Swedish filmjölk) on markers of oxidative stress and inflammation in a randomized crossover intervention study.

Read the detailed description

A diet rich in antioxidants reduces oxidative stress and inflammation and could potentially improve health and lower the rate of hip fracture. Milk and dairy are also promoted as part of a healthy diet since they contain 18 of 22 essential nutrients including calcium, phosphorous, and vitamin D and have been suggested to be associated with lower risk of cardiovascular disease, especially stroke, type 2 diabetes, and cancer. Meta-analyses of milk and dairy on fracture and mortality risk in cohort studies are, however, inconclusive and show significant heterogeneity between studies. Small intakes may have beneficial effects in comparison to null intake whereas higher intakes may have other effects and non-linear relationships are rarely examined. Frequently, different milk products are considered as one entity in cohort studies. The investigators recently showed that different milk products might have differential effects on disease. A high long-term milk intake was associated with an increased risk of mortality (total, cardiovascular, and cancer mortality) and hip fracture, especially among women, whereas a high long-term intake of fermented milk (soured milk and yogurt or cheese) was associated with a lower risk of mortality and fracture among women. Similar results have been presented for total mortality (Northern Sweden) and humeral fractures (South-Eastern Australia).

Intake of milk and fermented milk is of tradition high in Sweden. The prevalence of lactase persistence is high (around 95%). The range in milk intake from non- and low-consumers to high consumers makes Sweden an appropriate setting for epidemiological and interventional studies.

A common potential mechanism for intake of fruits, vegetables, and different dairy products on risk of disease is their influence on inflammation and oxidative stress. Chronic low-grade inflammation and age-related increase of oxidative stress are suggested pathogenic mechanisms of premature ageing and many diseases including cardiovascular disease, cancer, accelerated bone loss (leading to osteoporosis), and age-related reduction of muscle strength and mass (sarcopenia) with potential impacts on risk of falling and fracture. The lower risk of fractures with a high intake of fermented milk products observed may be due to potential probiotic, antioxidative, and anti-inflammatory effects and effects on gut microbiota. A high intake of milk was not only associated with risk of mortality and fractures but also with increased concentrations of inflammation and oxidative stress markers. An inverse association was seen for intake of soured milk and yogurt [Michaëlsson, 2014]. Fermented milk products with probiotics have been shown to reduce the levels of inflammation markers, other studies have been small to show conclusive effects and results may also be dependent on the probiotic strain. A head-to-head comparison of the effect of regular milk and soured milk (or yogurt) on markers of inflammation and oxidative stress in a randomized intervention study is warranted. The randomized crossover intervention study will be performed among both men and women.

The aim of the study is to examine the potentially different short-term effects of milk and sour milk on markers of oxidative stress and inflammation in a randomized cross-over trial. The research questions are:

  1. In a randomized cross-over trial, what is the effect of a daily intake of at least 500 ml of Swedish milk compared with an intake of at least 500 ml Swedish soured milk (filmjölk) during 3 weeks on markers of oxidative stress and inflammation?
  2. What are the effects of these milk products on a large number of proteins related with inflammation and ageing diseases, assessed with large-scale proteomic analysis?
  3. What are the effects of these milk products on metabolites involved in inflammation and ageing diseases using large-scale metabolomics analysis?
  4. What are the effects of these milk products on the gut microflora (microbiome)?

Changes in proteomics, metabolomics and the gut microbiome are other pre-specified outcome measures but since they are exploratory in nature, we do not specify them under outcomes since it is not possible to exactly specify these outcome measures. Exploratory analyses will include whether effects are different between men and women, dependent on body composition (assessed with whole body dual X-ray absorptiometry, DXA) or long-term dietary intake (assessed by fatty acid composition in subcutaneous fat). Participants will be allowed to consume more than 500 ml of milk/filmjölk during the intervention periods and, if possible, a potential dose-response effect will be evaluated.

02

Conditions studied

  • Oxidative Stress
  • Inflammation

Browse trials for

03

In context

Inflammation

3,441 studies on the registry are indexed under Inflammation; 631 are open to participants now.

This study's enrollment of 84 is above the median of 50 across 2,438 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Uppsala University is the lead sponsor of 381 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Tolerates both a low and a high intake of milk and soured milk
  • Agrees to comply with study protocol

Exclusion criteria

Exclusion Criteria:

  • Inflammatory bowel disease
  • Major gastric tract operation
  • Pregnancy
  • Eating disorder
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Milk

    At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.

    Other: Milk

  • Experimental
    Soured milk (filmjölk)

    At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.

    Other: Soured milk (filmjölk)

Interventions

  • OtherMilk

    Swedish milk from cow.

  • OtherSoured milk (filmjölk)

    Swedish soured milk (from cow milk).

06

What researchers measure

Primary outcomes

  1. Change in oxidative stress marker

    urinary 8-iso-prostaglandin F2 alpha (8-iso-PGF2alpha)

    Time frame: baseline and 3 weeks

  2. Change in oxidative stress marker

    urinary 8-iso-prostaglandin F2 alpha (8-iso-PGF2alpha)

    Time frame: 6 weeks and 9 weeks

Secondary outcomes

  1. Change in interleukin-6 (IL-6)

    Inflammation marker, measured in serum

    Time frame: baseline and 3 weeks

  2. Change in interleukin-6 (IL-6)

    Inflammation marker, measured in serum

    Time frame: 6 weeks and 9 weeks

  3. Change high sensitive C-reactive protein (hs-CRP)

    Inflammation marker, measured in serum

    Time frame: baseline and 3 weeks

  4. Change high sensitive C-reactive protein (hs-CRP)

    Inflammation marker, measured in serum

    Time frame: 6 weeks and 9 weeks

  5. Change in 15-keto-dihydro-prostaglandin F2 alpha (15-keto-dihydro-PGF2alpha)

    Inflammation marker, a major metabolite of prostaglandin F2alpha, measured in urine

    Time frame: baseline and 3 weeks

  6. Change in 15-keto-dihydro-prostaglandin F2 alpha (15-keto-dihydro-PGF2alpha)

    Inflammation marker, a major metabolite of prostaglandin F2alpha, measured in urine

    Time frame: 6 weeks and 9 weeks

07

Study locations

1 site
  • Forskningsmottagning bentäthet, Kirurgiska vetenskaper, Uppsala Universitet
    Uppsala, 75185, Sweden
08

References and documents

Publications

  • Larsson SC, Crippa A, Orsini N, Wolk A, Michaelsson K. Milk Consumption and Mortality from All Causes, Cardiovascular Disease, and Cancer: A Systematic Review and Meta-Analysis. Nutrients. 2015 Sep 11;7(9):7749-63. doi: 10.3390/nu7095363. PubMed 26378576 ↗
  • Michaelsson K, Wolk A, Langenskiold S, Basu S, Warensjo Lemming E, Melhus H, Byberg L. Milk intake and risk of mortality and fractures in women and men: cohort studies. BMJ. 2014 Oct 28;349:g6015. doi: 10.1136/bmj.g6015. PubMed 25352269 ↗
  • Tognon G, Nilsson LM, Shungin D, Lissner L, Jansson JH, Renstrom F, Wennberg M, Winkvist A, Johansson I. Nonfermented milk and other dairy products: associations with all-cause mortality. Am J Clin Nutr. 2017 Jun;105(6):1502-1511. doi: 10.3945/ajcn.116.140798. Epub 2017 May 10. PubMed 28490510 ↗
  • Holloway KL, Bucki-Smith G, Morse AG, Brennan-Olsen SL, Kotowicz MA, Moloney DJ, Sanders KM, Korn S, Timney EN, Dobbins AG, Pasco JA. Humeral Fractures in South-Eastern Australia: Epidemiology and Risk Factors. Calcif Tissue Int. 2015 Nov;97(5):453-65. doi: 10.1007/s00223-015-0039-9. Epub 2015 Jul 14. PubMed 26169198 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03821116
Lead sponsor
Uppsala University
Collaborators
Forte
Responsible party
Sponsor
First posted
Jan 29, 2019
Start date
Jan 7, 2019
Primary completion
Jun 9, 2020
Completion
Jun 9, 2020
Last update
Nov 4, 2020

Study contacts

Liisa Byberg, PhD
principal investigator · Department of Surgical Sciences, Uppsala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion